-
Collins Stewart Names Alexion Pharmaceuticals (ALXN) A Top Pick For 2010
Wednesday, April 14, 2010 - 9:44am
Collins Stewart analysts Salveen J. Kochnover and Laura A. Ekas reiterated their Buy rating for shares of biotechnology company Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), with a price target of $59 per share. The analysts said that the Alexion Pharmaceuticals pipeline should make significant...
Read More >> -
BioMarin Pharmaceutical, Inc. (BMRN) One Of Top Picks Of 2010
Friday, February 5, 2010 - 9:58amAnalysts Salveen J. Kochnover and Brent Kelly at Collins Stewart have released an update on BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN). Analysts have a Buy rating for the company. According to analysts, the company remains one of their top picks for 2010 due to an attractive pipeline, strong top...
Read More >>
